Endurant Capital Management LP acquired a new position in iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) during the fourth quarter, HoldingsChannel reports. The institutional investor acquired 21,041 shares of the company’s stock, valued at approximately $411,000. Other hedge funds also recently made changes to their positions in the company. American International Group Inc. raised its […]
Tang Capital Management LLC trimmed its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) by 76.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 216,700 shares of the company’s stock after selling 720,800 shares during the […]
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) was the recipient of a large increase in short interest in the month of May. As of May 15th, there was short interest totalling 1,780,000 shares, an increase of 6.6% from the April 30th total of 1,670,000 shares. Approximately 6.1% of the company’s stock are sold short. Based […]
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating)’s share price traded down 6.3% during mid-day trading on Tuesday . The stock traded as low as $16.51 and last traded at $16.91. 145,109 shares traded hands during mid-day trading, a decline of 45% from the average session volume of 264,273 shares. The stock had previously closed at […]
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) – Equities researchers at HC Wainwright upped their Q2 2023 EPS estimates for shares of iTeos Therapeutics in a note issued to investors on Thursday, May 11th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($1.13) for the quarter, up […]